![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 330792-70-6
2. 3-amino-5-(4-phenoxyphenyl)pyrazole-4-carbonitrile
3. 3-amino-5-(4-phenoxyphenyl)-1h-pyrazole-4-carbonitrile
4. 1h-pyrazole-4-carbonitrile, 3-amino-5-(4-phenoxyphenyl)-
5. 3-amino-4-cyano-5-(4-phenoxyphenyl)pyrazole
6. Mfcd28137676
7. Schembl202119
8. Schembl15472736
9. Amy8943
10. Dtxsid40625079
11. Bcp11040
12. Cs-m2596
13. Zinc82049716
14. Akos016003989
15. Ac-28743
16. Cs-13107
17. Da-24246
18. Sy033527
19. Ft-0754454
20. 3-amino-4-cyano-5-(4-phenoxypheny1)pyrazole
21. S10997
22. A855834
23. Nitrilotriaceticacidtrisodiumsaltmonohydrate
24. J-019007
25. 3-amino-5-(4-phenoxyphenyl)-(1h)-pyrazole-4-carbonitrile
26. 5-amino-3-(4-phenoxy Phenyl)-1h-pyrazole-4-carbonitrile
Molecular Weight | 276.29 g/mol |
---|---|
Molecular Formula | C16H12N4O |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 276.10111102 g/mol |
Monoisotopic Mass | 276.10111102 g/mol |
Topological Polar Surface Area | 87.7 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 379 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.